Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1111-1120

  Peñas LLedó, Eva M ^a   Dorado, Pedro ^a   Pacheco, Rodrigo ^a   González, Idilio ^b   Llerena, Adrián ^a,c  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b LLerena Hospital Servicio Extremeño de Salud SES   (Spain)

^c Faculdade de Ciências da Saúde   (Portugal)

Author keywords

CANTAB ; CYP2D6; Impulsivity; KSP; Personality; Pharmacogenetics; Pharmacogenomics; SCL 90 R; TCI R

Indexed keywords

CYTOCHROME P450 2D6; DOPAMINE; SEROTONIN;

ADULT; AFFECT; AGE; ATTENTION; BEHAVIOR GENETICS; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PAIRED ASSOCIATE LEARNING; PERSONALITY; SEX; SPAIN; SPATIAL MEMORY; SYMPTOM CHECKLIST 90; VOLUNTEER; VULNERABLE POPULATION; WORKING MEMORY;

ADOLESCENT; ADULT; COGNITION; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PERSONALITY; PSYCHOPATHOLOGY; TEMPERAMENT; YOUNG ADULT;

EID: 70449516166     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.75     Document Type: Conference Paper

References (40)

1. Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S: Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J. Pharmacol. Exp. Ther. 268(2), 546-551 (1994).
2. LLerena A, Dorado P, Peñas-LLedó EM: Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10(1), 17-28 (2009).
3. Dorado P, Berecz R, Peñas-LLedó EM, Cáceres MC, LLerena A: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr. Drug Targets 7(12), 1671-1680 (2006).
4. Miksys SL, Tyndale RF: Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 27(6), 406-415 (2002).
5. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13(3), 173-181 (2003). (Pubitemid 36324247)
6. Yu AM, Idle JR, Gonzalez FJ: Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 36(2), 243-277 (2004). ■■ This in vivo study shows that the polymorphic CYP2D6 may play an important role in the interconversions of psychoactive tryptamines, including a crucial step in a serotonin-melatonin cycle.
7. Dorado P, Peñas-LLedó EM, LLerena A: CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8(11), 1597-1608 (2007). (Pubitemid 350286402)
8. Ozdemir V, Bertilsson L, Miura J et al.: CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet. Genomics 17(5), 339-347 (2007). ■■ Suggests that CYP2D6 genetic variation may potentially influence pharmacodynamic tissue sensitivity in the brain through disposition of an endogenous substrate.
9. Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V: CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet. Genomics 17(11), 989-993 (2007). (Pubitemid 350293798)
10. LLerena A: Metabolización hepática de fármacos: interacciones genético-ambientales en el polimorfismo de debrisoquina. PhD Thesis. University of Extremadura, Badajoz, Spain (1988).
11. LLerena A, Cobaleda J, Benítez J: Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet 1(8651), 1398 (1989).
12. González I, Peñas-LLedó EM, Pérez B, Dorado P, Alvarez M, LLerena A: Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9(7), 833-840 (2008). ■■ First study that replicated the study of LLerena et al. (1993) [14] in a similar population of healthy volunteers but in a different country (Cuba) showing very similar personality differences (Karolinska Scales of Personality) with regard to different degrees of CYP2D6 activity (debrisoquine hydroxylation phenotype).
13. Bertilsson L, Alm C, de las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism and personality. Lancet 1(8637), 555 (1989). ■■ First study that explored the relationship between personality traits with the Karolinska Scales of Personality and debrisoquine hydroxylation phenotype (poor metabolizers vs extensive metablizers) in a Swedish population of healthy volunteers.
14. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P-4502D6. Acta Psychiatr. Scand. 87(1), 23-28 (1993). ■■ First study in a large sample of healthy volunteers in Spain showing personality differences (Karolinska Scales of Personality) with regard to different degrees of CYP2D6 activity (debrisoquine hydroxylation phenotype).
15. Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET: Relationship between type A and B personality and debrisoquine hydroxylation capacity. Br. J. Clin. Pharmacol. 57(6), 785-789 (2004). (Pubitemid 38748046)
16. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA: Association between cytochrome P450 2D6 genotype and harm avoidance. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127(1), 90-93 (2004).
17. Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J: Association of CYP2D6 genotypes and personality traits in healthy individuals. J. Clin. Psychopharmacol. 26(4), 440-442 (2006). (Pubitemid 44187657)
18. Iwashima K, Yasui-Furukori N, Kaneda A et al.: No association between CYP2D6 polymorphisms and personality trait in Japanese. Br. J. Clin. Pharmacol. 64, 96-99 (2007). (Pubitemid 46934423)
19. Suzuki E, Kitao Y, Ono Y, Iijima Y, Inada T: Cytochrome P450 2D6 polymorphism and character traits. Psychiatr. Genet. 13, 111-113 (2003). (Pubitemid 36724541)
20. Flaa A, Ekeberg O, Kjeldsen SE, Rostrup M: Personality may influence reactivity to stress. Biopsychosoc. Med. 1, 5 (2007).
21. Shtasel DL, Gur RE, Mozley PD et al.: Volunteers for biomedical research. Recruitment and screening of normal controls. Arch. Gen. Psychiatry. 48, 1022-1025 (1991).
22. Tishler CL, Apseloff G, Bartholomae S, Reiss NS, Rhodes AR, Singh A: Are normal healthy research volunteers psychologically healthy? A pilot investigation. Exp. Clin. Psychopharmacol. 15, 539-545 (2007). (Pubitemid 351163128)
23. Bunce SC, Noblett KL, McCloskey MS, Coccaro EF: High prevalence of personality disorders among healthy volunteers for research: implications for control group bias. J. Psychiatr. Res. 39, 421-430 (2005).
24. Cools R, Roberts AC, Robbins TW: Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn. Sci. 12, 31-40 (2008). (Pubitemid 50012215)
25. Cools R: Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14, 381-395 (2008).
26. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, LLerena A: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39(4), 571-574 (2005).
27. Schalling D, Asberg M, Edman G, Oreland L: Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity. Acta Psychiatr. Scand. 76(2), 172-182 (1987).
28. Ortet G, Ibáñez M, LLerena A, Torrubia R: The underlying traits of the Karolinska Scales of Personality (KSP). Eur. J. Psychological Assess. 18(2), 139-148 (2002).
29. Gutiérrez-Zotes JA, Bayón C, Montserrat C et al.: [Temperament and Character Inventory Revised (TCI-R). Standardization and normative data in a general population sample]. Actas Esp. Psiquiatr. 32, 8-15 (2004).
30. González de Rivera JL, Derogatis LR, de las Cuevas C et al.: The Spanish version of the SCL-90-R. In: Normative Data in The General Population Clinical Psychometric Research. Towson, MD, USA (1989).
31. Holi MM, Marttunen M, Aalberg V: Comparison of the GHQ-36, the GHQ-12 and the SCL-90 as psychiatric screening instruments in the Finnish population. Nord. J. Psychiatry. 57(3), 233-238 (2003). (Pubitemid 36805997)
32. Robles JI, Andreu JM, Peña ME: SCL-90-R: Aplicación y análisis de las propiedades psicométricas en una muestra de sujetos clínicos españoles. Psicopatología clínica, legal y forense 2, 1-19 (2002).
33. Bellgrove MA, Mattingley JB: Molecular genetics of attention. Ann. NY Acad. Sci. 1129, 200-212 (2008).
34. Spencer T, Biederman J, Wilens T et al.: Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch. Gen. Psychiatry 58(8), 775-782 (2001). (Pubitemid 32717803)
35. Bellgrove MA, Hawi Z, Gill M, Robertson IH: The cognitive genetics of attention deficit hyperactivity disorder (ADHD): Sustained attention as a candidate phenotype. Cortex 42(6), 838-845 (2006). (Pubitemid 46768738)
36. Silber BY, Croft RJ, Papafotiou K, Stough C: The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187(2), 154-169 (2006). (Pubitemid 44015610)
37. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ: Serotonin and human cognitive performance. Curr. Pharm. Des. 12(20), 2473-2486 (2006).
38. Matrenza C, Hughes JM, Kemp AH, Wesnes KA, Harrison BJ, Nathan PJ: Simultaneous depletion of serotonin and catecholamines impairs sustained attention in healthy female subjects without affecting learning and memory. J. Psychopharmacol. 18(1), 21-31 (2004). (Pubitemid 38623090)
39. LLerena A, Dorado P, Peñas-LLedó EM, Cáceres MC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. 7(6), 408-410 (2007). (Pubitemid 350187452)
40. Cambridge Cognition Ltd: CANTAB® www.cantab.com